

CITATION REPORT

List of articles citing

Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin

DOI: 10.1111/jth.13577

Journal of Thrombosis and Haemostasis, 2017, 15, 273-283.

Source: <https://exaly.com/paper-pdf/66356332/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
93	Drug interactions with new oral anticoagulants in elderly patients. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1191-1202	3.8	23
92	Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. <i>Thrombosis Research</i> , 2017 , 158, 126-133	8.2	19
91	An injectable in situ lipid phase transition system for sustained delivery of dabigatran etexilate with low burst release. <i>RSC Advances</i> , 2017 , 7, 56594-56601	3.7	2
90	PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 416-421	0.5	2
89	DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 716-724	0.5	
88	Pathogenesis of thrombosis: cellular and pharmacogenetic contributions. <i>Cardiovascular Diagnosis and Therapy</i> , 2017 , 7, S291-S298	2.6	6
87	Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1301-1312	3.8	18
86	Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 611-618	2.8	3
85	Clinical Review of the Pharmacogenomics of Direct Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 121-126	3.9	6
84	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. <i>Thrombosis Journal</i> , 2018 , 16, 28	5.6	25
83	Influence of and gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 43-49	2.1	18
82	Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. <i>Personalized Medicine</i> , 2018 , 15, 209-221	2.2	10
81	Macrolides, Azalides, and Ketolides. 2018 , 57-86		
80	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018 , 19, 913-925	2.6	10
79	Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With and Genetic Defect. <i>Frontiers in Pharmacology</i> , 2018 , 9, 491	5.6	8
78	Stochastic proximal-gradient algorithms for penalized mixed models. <i>Statistics and Computing</i> , 2019 , 29, 231-253	1.8	3
77	BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 138, 105039	5.1	26

76	Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins. <i>Molecular Pharmaceutics</i> , 2019 , 16, 4065-4076	5.6	4
75	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019 , 26, 413-420	2.9	7
74	Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, 738-744	2.5	4
73	Potential usefulness of activated charcoal (DOAC remove) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. <i>Thrombosis Research</i> , 2019 , 184, 86-91	8.2	20
72	Oral Anticoagulant Therapy-When Art Meets Science. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6
71	Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. <i>Journal of Personalized Medicine</i> , 2019 , 9,	3.6	37
70	Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 449-458	5.5	5
69	Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1670-1682	15.4	15
68	Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2848-2864	5.1	4
67	Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review. <i>Analytica Chimica Acta</i> , 2019 , 1076, 18-31	6.6	14
66	Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 817-824	2.8	6
65	Pharmacogenomic Testing for Postoperative Pain Optimization Before Total Joint Arthroplasty: A Focus on Drug-Drug-Gene Interaction with Commonly Prescribed Drugs and Prior Opioid Use. <i>JBJS Reviews</i> , 2019 , 7, e2	2.6	1
64	Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 180-191	3.2	14
63	P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. <i>Journal of Hypertension</i> , 2019 , 37, 2225-2231	1.9	3
62	Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage. <i>Stroke</i> , 2019 , 50, 529-536	6.7	15
61	Drug-drug-gene interactions and adverse drug reactions. <i>Pharmacogenomics Journal</i> , 2020 , 20, 355-366	3.5	40
60	Modulation of expression/function of intestinal P-glycoprotein under disease states. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 59-78	5.5	11
59	An Exploratory Association Analysis of rs1045642 and rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	2

58	[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020]. <i>Bulletin Du Cancer</i> , 2020 , 107, 574-585	2.4	0
57	Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. <i>Medicine (United States)</i> , 2020 , 99, e22084	1.8	2
56	Simple LC-MS/MS method using core-shell ODS microparticles for the simultaneous quantitation of edoxaban and its major metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1146, 122121	3.2	1
55	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020 , 80, 1065-1083	12.1	13
54	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. <i>JAMA Internal Medicine</i> , 2020 , 180, 1052-1060	11.5	16
53	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. <i>Advances in Therapy</i> , 2020 , 37, 3537-3550	4.1	4
52	Drug-Drug Interactions with Direct Oral Anticoagulants. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 967-980	6.2	34
51	May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. <i>Pharmacogenomics and Personalized Medicine</i> , 2020 , 13, 29-37	2.1	4
50	Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020 , 148, 27-37	5.7	1
49	Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 128, 297-304	3.1	3
48	Pharmacodynamics and Pharmacokinetics of Stroke Therapy. 2021 , 41-69		
47	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. <i>TH Open</i> , 2021 , 5, e84-e88	2.7	1
46	Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	19
45	ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 369-396	5.5	11
44	Pharmacogenetics of Direct Oral Anticoagulants.		0
43	Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	0
42	Pharmacokinetics and Pharmacogenetics of Dabigatran. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 146-152	0.5	1
41	Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. <i>Biomedicines</i> , 2021 , 9,	4.8	7

40	The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects. <i>Pharmacogenomics and Personalized Medicine</i> , 2021 , 14, 477-485	2.1	1
39	Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 768-776	6.1	6
38	Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation. <i>Frontiers in Pharmacology</i> , 2021 , 12, 614762	5.6	0
37	ATP-binding cassette transporters and neurodegenerative diseases. <i>Essays in Biochemistry</i> , 2021 ,	7.6	2
36	Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1526-1536	6.1	6
35	The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure. <i>Frontiers in Pharmacology</i> , 2021 , 12, 723905	5.6	1
34	Inflammation Induces Changes in the Functional Expression of P-gp, BCRP, and MRP2: An Overview of Different Models and Consequences for Drug Disposition. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
33	Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 165, 105932	5.1	1
32	Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 821-830	2.5	0
31	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. <i>Vestnik Rossijskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 299-306	0.4	1
30	Promising areas of research on the pharmacogenetics of dabigatran etexilate. <i>Farmakogenetika i Farmakogenomika</i> , 2020 , 35-41	0.2	1
29	Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes. <i>Thrombosis Research</i> , 2021 , 208, 39-44	8.2	2
28	Drug-drug interactions of warfarin and new direct oral anticoagulants. <i>Medicina Pro Praxi</i> , 2018 , 15, 267-275		1
27	Importance des interactions médicamenteuses réfastes chez le patient oncologique : comparaison de programmes de d'ection informatisé. <i>Douleur Et Analgesie</i> , 2019 , 32, 21-36	0.2	
26	Practical issues in measuring the anticoagulant effect of direct oral anticoagulants. <i>Arhiv Za Farmaciju</i> , 2020 , 70, 297-309	0.2	
25	New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants. <i>Rational Pharmacotherapy in Cardiology</i> , 2020 , 16, 670-677	0.5	0
24	Use of direct oral anticoagulants in daily practice. <i>American Journal of Blood Research</i> , 2018 , 8, 57-72	1.6	17
23	Serum or Plasma for Quantification of Direct Oral Anticoagulants?. <i>Therapeutic Drug Monitoring</i> , 2022 ,	3.2	1

22	A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 814724	5.6	1
21	Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	1
20	Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.. <i>Acta Pharmacologica Sinica</i> , 2022 ,	8	2
19	Peculiarities of dabigatran pharmacogenetics: literature review. <i>Journal of Arrhythmology</i> , 2022 , 29, 39-44	4.3	0
18	Video_1.mp4. 2018 ,		
17	Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions and Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	1
16	The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation.		1
15	Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non-valvular atrial fibrillation.		
14	Pharmacogenomics Informs Cardiovascular Pharmacotherapy. 2022 , 201-240		0
13	A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran. 2022 , 19, 332		0
12	Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?. 2022 , 11, 6369		0
11	Effect of Genotype on the Pharmacokinetics and Bleeding Events of Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.		0
10	Individual Pharmacotherapy Management (IPM)IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy. 2022 , 11, 1381		0
9	Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. 2022 , 32, 301-307		0
8	Assessment of DOAC in GEriatics (ADAGE study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAf very elderly patients.		0
7	Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis. 2023 , 18, 624-629		0
6	Risk Factors for Rivaroxaban-Related Bleeding EventsPossible Role of Pharmacogenetics: Case Series. 2023 , 11, 29		0
5	Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis. 2023 , 24, 3303		0

- 4 Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers. **2023**, 19, 43-51
- 3 Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach.
- 2 Evidence of potential pro-haemorrhagic drug interactions between CYP3A4 inhibitors and direct oral anticoagulants: Analysis of the FAERS database.
- 1 Challenges of Anticoagulant Therapy in Atrial Fibrillation Focus on Gastrointestinal Bleeding. **2023**, 24, 6879